Patents Issued in May 7, 2019
-
Patent number: 10280404Abstract: The present invention relates to nucleic acid sequences that encode hepatitis C viruses (HCV) that are useful in the fundamental research of HCV as well as in the search of a vaccine against HCV. In particular the present invention relates to nucleic acid sequences that comprises HCVs which are capable of expressing said virus when transfected into cells and are capable of infectivity in vivo.Type: GrantFiled: October 23, 2015Date of Patent: May 7, 2019Assignees: Hvidovre Hospital, Københavns UniversitetInventors: Jens Bukh, Yiping Li, Santseharay Ramirez Almeida
-
Patent number: 10280405Abstract: The present invention provides methods of propagating rhinovirus C (RV-C) in a host cell; a host cell comprising an effective amount of a heterologous CDHR3 receptor such that the host cell can support propagation of rhinovirus C; and kits comprising at least one host cell previously unable to support rhinovirus C growth, wherein the host cell comprises a heterologous CDHR3 receptor and a sample of rhinovirus C. Methods of use are also provided.Type: GrantFiled: March 6, 2018Date of Patent: May 7, 2019Assignee: Wisconsin Alumni Research FoundationInventors: James E. Gern, Yury A. Bochkov, Ann C. Palmenberg
-
Patent number: 10280406Abstract: The object of the present invention is to efficiently produce useful terpenoid compounds, and specifically, to provide a method for preparing squalene, which is an important intermediate of terpenoid. The object can be solved by a hydroxymethylglutaryl CoA reductase (HMGR) comprising: (a) an amino acid other than alanine (A) at the 10th position in an S?2 amino acid sequence of HMGR, (b) an amino acid other than proline (P) at the 1st position from the carboxyl terminal in the DKK region of the HMG-CoA binding site of HMGR, (c) an amino acid other than alanine (A) at the 1st position in an L?2 amino acid sequence of HMGR, and (d) an amino acid other than glutamic acid (E) at the 6th position in an L?2 amino acid sequence of HMGR of the present invention.Type: GrantFiled: April 9, 2015Date of Patent: May 7, 2019Assignee: ADEKA CORPORATIONInventors: Toshihiko Takehana, Seiji Koike, Tomohisa Kuzuyama
-
Patent number: 10280407Abstract: The present invention concerns a recombinant strain belonging to the order of Actinomycetales, wherein at least one gene encoding an enzyme having vanillin reductase activity is non-functional. The present invention is also related to a process for producing vanillin or a precursor thereof, comprising the culture of a recombinant strain in an appropriate medium comprising a substrate, and recovery of the produced vanillin or precursor thereof.Type: GrantFiled: June 30, 2015Date of Patent: May 7, 2019Assignee: Rhodia OperationsInventors: Mirjana Gelo-Pujic, Antoine Amory
-
Patent number: 10280408Abstract: The present invention relates to methods of suppressing the transcriptional expression of one or more genes by methylating the chromatin histone proteins of the one or more genes. Specifically, a viral SET domain histone lysine mehtyltransferase (vSET or vSET-like protein) methylates lysine 27 of a gene's histone protein 3 (H3-K27) thereby suppressing the transcription of the gene.Type: GrantFiled: January 21, 2016Date of Patent: May 7, 2019Assignee: ICAHN SCHOOL OF MEDICINE AT MOUNT SINAIInventors: Ming-ming Zhou, Shiraz Mujtaba
-
Patent number: 10280409Abstract: The present invention relates to high level expression of bacterial toxoid or toxin protein of pharmacological interest by means of an optimized novel polynucleotide sequence and host transformed with the said polynucleotide. Specifically, the invention provides a method for high production of polypeptide CRM197 wherein, the polynucleotide of the invention is used to transform a suitable host resulting in over-expression of corresponding proteins and a method for isolating the expressed polypeptide. More particularly, the present invention relates to high level expression of CRM197 in Escherichia coli and a method for the isolation and purification thereof.Type: GrantFiled: November 17, 2015Date of Patent: May 7, 2019Assignee: BIOLOGICAL E LIMITEDInventors: Akshay Goel, Ravi Pratap Narayan Mishra, Narender Dev Mantena, Mahima Datla
-
Patent number: 10280410Abstract: The disclosure relates to a cytoplasmic protein complex comprising: (a) a first recombinant fusion protein comprising a kinase, fused to a first interaction polypeptide; and (b) a second recombinant fusion protein comprising a domain comprising a reporter phosphorylation site, whereby the domain is fused to a second interaction polypeptide. The disclosure relates further to a method to detect compound-compound-interaction using the cytoplasmic protein complex, and to cells comprising such cytoplasmic protein complex.Type: GrantFiled: February 29, 2012Date of Patent: May 7, 2019Assignees: UNIVERSITEIT GENT, VIB VZWInventors: Jan Tavernier, Samuel Lievens
-
Patent number: 10280411Abstract: Provided are compositions comprising recombinant polymerases that include amino acid substitutions, insertions, deletions, and/or exogenous features that confer modified properties upon the polymerase for sequencing RNA or RNA/DNA templates. Polymerases that topologically encircle the template nucleic acid are provided. Also provided are methods of using such polymerases to make a DNA or to sequence a template comprising RNA.Type: GrantFiled: October 26, 2016Date of Patent: May 7, 2019Assignee: Pacific Biosciences of California, In.cInventors: Satwik Kamtekar, Jeremiah Hanes, Erik Miller
-
Patent number: 10280412Abstract: Provided are a mismatch-specific cleavage reaction using a novel heat-resistant mismatch nuclease, a method for removing errors in a nucleic acid amplification reaction using the mismatch nuclease, a method for inhibiting the amplification of a nucleic acid having a specific base sequence during a nucleic acid amplification reaction, and a method for detecting a nucleic acid having a single-base polymorphic mutation using this inhibition method.Type: GrantFiled: December 12, 2018Date of Patent: May 7, 2019Assignee: TAKARA BIO INC.Inventors: Kiyoyuki Matsumura, Nariaki Takatsu, Takashi Uemori, Hiroyuki Mukai
-
Patent number: 10280413Abstract: The present invention relates to isolated polypeptides having cellobiohydrolase activity and polynucleotides encoding the polypeptides. The invention also relates to nucleic acid constructs, vectors, and host cells comprising the polynucleotides as well as methods of producing and using the polypeptides.Type: GrantFiled: September 27, 2017Date of Patent: May 7, 2019Assignee: Novozymes, Inc.Inventor: Nikolaj Spodsberg
-
Patent number: 10280414Abstract: Multimeric protein structures comprising at least two alpha-galactosidase monomers being covalently linked to one another via a linking moiety are disclosed herein, as well a process for preparing same, and methods of treating Fabry disease via administration of a multimeric protein structure. The disclosed multimeric protein structures exhibit an improved performance, in terms of enhanced activity and/or a longer lasting activity under both lysosomal conditions and in a serum environment.Type: GrantFiled: June 29, 2017Date of Patent: May 7, 2019Assignee: Protalix Ltd.Inventors: Avidor Shulman, Ilya Ruderfer, Tehila Ben-Moshe, Talia Shekhter, Yaniv Azulay, Tali Kizhner, Yoseph Shaaltiel
-
Patent number: 10280415Abstract: Human cystathionine ?-synthase variants are disclosed, as well as a method to produce recombinant human cystathionine ?-synthase and variants thereof. More particularly, the role of both the N-terminal and C-terminal regions of human CBS has been studied, and a variety of truncation mutants and modified CBS homologs are described. In addition, a method to express and purify recombinant human cystathionine ?-synthase (CBS) and variants thereof which have only one or two additional amino acid residues at the N-terminus are described.Type: GrantFiled: March 14, 2017Date of Patent: May 7, 2019Assignee: THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATEInventor: Jan P. Kraus
-
Patent number: 10280416Abstract: Described herein are methods for making and using magnetic ionic liquid that have at least one cationic component and at least one anionic component, where at least one of the cationic components or the anionic components is a paramagnetic component. The magnetic ionic liquids are capable of manipulation by an external magnetic field.Type: GrantFiled: February 19, 2016Date of Patent: May 7, 2019Assignee: The University of ToledoInventors: Jared L. Anderson, Omprakash Nacham, Kevin D. Clark
-
Patent number: 10280417Abstract: Aspects of the invention relate to methods, compositions for synthesizing oligonucleotides having a predefined sequence.Type: GrantFiled: March 13, 2014Date of Patent: May 7, 2019Assignee: Gen 9, Inc.Inventors: Giles F. Hall, Scott S. Lawton
-
Patent number: 10280418Abstract: The invention relates to inhibitory nucleic acids and rAAV-based compositions, methods and kits useful for treating Amyotrophic Lateral Sclerosis.Type: GrantFiled: March 18, 2015Date of Patent: May 7, 2019Assignee: Univeristy of MassachusettsInventors: Christian Mueller, Robert H. Brown, Jr.
-
Patent number: 10280419Abstract: Methods and products are described related to use of the CRISPR/Cas9 system to introduce a modification into an APP gene, such as guide RNAs and recombinant proteins, for decreasing amyloid beta peptide produced by a cell. Also described are uses of such methods and products for the treatment of Alzheimer's disease and/or age-related cognitive decline in a cell from a subject in need thereof.Type: GrantFiled: May 8, 2015Date of Patent: May 7, 2019Assignee: UNIVERSITÉ LAVALInventors: Jacques P. Tremblay, Joël Rousseau, Pierre Chapdelaine
-
Patent number: 10280420Abstract: The present invention relates to a recombination vector, a transformation cell into which the recombinant vector is introduced, a ribozyme expressed from the recombination vector, a prophylactic or therapeutic composition for liver cancer comprising the recombination vector and the ribozyme, and a therapeutic method for liver cancer using the composition, said recombination vector comprising: a tissue-specific promoter; and a ribozyme-target gene expression cassette comprising a trans-splicing ribozyme targeting a cancer-specific gene and a target gene connected to the 3? exon of the ribozyme, wherein a splicing donor/splicing acceptor sequence (SD/SA sequence) is connected to the 5? end of the ribozyme-target gene expression cassette, woodchuck hepatitis virus posttranscriptional regulatory element (WPRE) is connected to the 3? end of the ribozyme-target gene expression cassette, and a nucleic acid sequence recognizing a micro RNA-122a (microRNA-122a, miR-122a) is further connected to the 3? end of the WPRE.Type: GrantFiled: July 23, 2015Date of Patent: May 7, 2019Assignee: RZNOMICS INC.Inventors: Seong Wook Lee, Ju Hyun Kim, Jin Sook Jeong, Sang Young Han
-
Patent number: 10280421Abstract: The present invention relates to antisense oligonucleotides that modulate the expression of and/or function of Interferon Regulatory Factor 8 (IRF8), in particular, by targeting natural antisense polynucleotides of Interferon Regulatory Factor 8 (IRF8). The invention also relates to the identification of these antisense oligonucleotides and their use in treating diseases and disorders associated with the expression of IRF8.Type: GrantFiled: October 31, 2017Date of Patent: May 7, 2019Assignee: CuRNA, Inc.Inventors: Joseph Collard, Olga Khorkova Sherman
-
Patent number: 10280422Abstract: The present invention provides oligonucleotide inhibitors of miR-92 and methods of using said inhibitors for inhibiting the function and/or activity of miR-92 in a subject in need thereof. The present invention also provides methods for evaluating or monitoring the efficacy of a therapeutic for promoting wound healing and selecting a subject for treatment with a therapeutic that modulates miR-92 function and/or activity.Type: GrantFiled: January 23, 2018Date of Patent: May 7, 2019Assignee: MIRAGEN THERAPEUTICS, INC.Inventors: Christina Marie Dalby, Corrie Lynn Gallant-Behm, Aimee Jackson, Kathryn Hutnick, Anita Seto
-
Patent number: 10280423Abstract: The present embodiments provide methods, compounds, and compositions for treating, preventing, or ameliorating a disease associated with dysregulation of the complement alternative pathway by administering a Complement Factor B (CFB) specific inhibitor to a subject.Type: GrantFiled: May 1, 2015Date of Patent: May 7, 2019Assignee: Ionis Pharmaceuticals, Inc.Inventors: Thazha P. Prakash, Punit P. Seth, Eric E. Swayze, Tamar R. Grossman, Michael L. McCaleb, Susan M. Freier
-
Patent number: 10280424Abstract: The present invention relates to a covalently closed DNA construct, a pharmaceutical composition and a vaccine and their use for the modulation of the immune system. It provides a DNA construct for immunomodulation comprising a specific DNA sequence.Type: GrantFiled: February 18, 2015Date of Patent: May 7, 2019Assignee: Mologen AGInventors: Christiane Kleuss, Kerstin Kapp, Burghardt Wittig, Matthias Schroff
-
Patent number: 10280425Abstract: Provided are a minicircle DNA recombinant parental plasmid having a genetically engineered antibody gene expression cassette and a preparation method for the plasmid, a minicircle DNA having the genetically engineered antibody gene expression cassette, a preparation method for the DNA, and applications thereof, and, a host cell having the minicircle DNA, a preparation method for the cell, and applications thereof. Also provided are a genetically engineered antibody, a preparation method for same, and applications thereof.Type: GrantFiled: August 5, 2014Date of Patent: May 7, 2019Assignees: Shenzhen Institutes of Advanced Technology, Shenzhen Hornetcorn Biotechnology Company, Ltd.Inventors: Zhiying Chen, Fei Ma, Chengyi He
-
Patent number: 10280426Abstract: A bacterial host cell is disclosed including at least two copies of an amplification unit in its genome, the amplification unit including: i) at least one copy of a gene of interest, and ii) an expressible conditionally essential gene, wherein the conditionally essential gene is either promoterless or transcribed from a heterologous promoter having an activity substantially lower than the endogenous promoter of the conditionally essential gene, and wherein the conditionally essential gene if not functional would render the cell auxotrophic for at least one specific substance or unable to utilize one or more specific sole carbon source; methods for producing a protein using the cell of the invention, and methods for constructing the cell of the invention.Type: GrantFiled: August 31, 2016Date of Patent: May 7, 2019Assignee: Novozymes A/SInventors: Carsten Olsen, Michael Dolberg Rasmussen
-
Patent number: 10280427Abstract: The present invention relates to a nucleic acid molecule that comprises at least one synthetic GAL1 core promoter containing one or more ligand responsive operator sequences, preferably one or more FadR operator sites; at least one upstream enhancer element (UEE); and at least one nucleotide sequence encoding for one or more genes of interest; wherein the at least one synthetic GAL1 core promoter is operably linked to the at least one nucleotide sequence encoding for one or more genes of interest and the at least one UEE is operably linked to the at least one synthetic GAL1 core promoter. Also encompassed are expression systems and recombinant cells that include these nucleic acid molecules and methods that use these nucleic acid molecules, expression systems or cells.Type: GrantFiled: January 20, 2014Date of Patent: May 7, 2019Assignee: NANYANG TECHNOLOGICAL UNIVERSITYInventors: Matthew Wook Chang, Wei Suong Teo
-
Patent number: 10280428Abstract: The present invention provides compositions and methods for the genetic manipulation of Algal cells. The compositions and methods allow enhanced transfer of genetic material into Algal cells and the cloning and selection of genetically modified cells. Expression of proteins encoded by the genetic material will be enhanced by the methods and compositions of the invention.Type: GrantFiled: December 13, 2017Date of Patent: May 7, 2019Assignee: LIFE TECHNOLOGIES CORPORATIONInventors: Farzad Haerizadeh, Todd Peterson, Wen Chen, Ewa Lis
-
Patent number: 10280429Abstract: This disclosure concerns compositions and methods for promoting transcription of a nucleotide sequence in a plant or plant cell, employing a promoter from a Zea mays KN1 gene. Some embodiments relate to a promoter from a Zea mays KN1 gene that functions in plants to promote transcription of operably linked nucleotide sequences.Type: GrantFiled: October 20, 2016Date of Patent: May 7, 2019Assignee: Dow AgroSciences LLCInventors: John Davies, David Mann, James Patrick Connell, William T. Beeson, IV
-
Patent number: 10280430Abstract: The present invention is in the field of plant genetics and provides recombinant nucleic acid molecules, constructs, and other agents associated with the coordinate manipulation of multiple genes in the fatty acid synthesis pathway. In particular, the agents of the present invention are associated with the simultaneous enhanced expression of certain genes in the fatty acid synthesis pathway and suppressed expression of certain other genes in the same pathway. Also provided are plants incorporating such agents, and in particular plants incorporating such constructs where the plants exhibit altered seed oil compositions.Type: GrantFiled: June 27, 2014Date of Patent: May 7, 2019Assignee: Monsanto Technology LLCInventors: Toni Voelker, JoAnne J. Fillatti, Neal A. Bringe, Tim Ulmasov
-
Patent number: 10280431Abstract: Provided herein are novel acyltransferases and methods of using such novel acyltransferases in making medium-chain fatty acids.Type: GrantFiled: December 18, 2014Date of Patent: May 7, 2019Assignee: NUtech VenturesInventors: Edgar Cahoon, Umidjon Iskandarov, Hae Jin Kim, Jillian Collins-Silva
-
Patent number: 10280432Abstract: The invention relates to genetically modified agricultural plants with increased oil content in vegetative tissues, as well as to expression systems, plant cells, seeds and vegetative tissues related thereto.Type: GrantFiled: April 13, 2017Date of Patent: May 7, 2019Assignee: Board of Trustees of Michigan State UniversityInventors: Christoph Benning, Sanjaya
-
Patent number: 10280433Abstract: The present invention provides methods and compositions for producing elite lines of corn exhibiting anthracnose stalk rot (ASR) resistance. Also provided in the present invention are corn plants exhibiting ASR resistance resulting from such methods, and methods for breeding corn such that the ASR resistance traits may be transferred to a desired genetic background.Type: GrantFiled: July 16, 2015Date of Patent: May 7, 2019Assignee: Monsanto Technology LLCInventors: George J. Baley, Derek R. Drost, Hongwu Jia, Yule Pan, Jeffrey Michael Stein, Chongqing Xie, Hao Zhou
-
Patent number: 10280434Abstract: Compositions and methods for conferring pesticidal activity to bacteria, plants, plant cells, tissues and seeds are provided. Compositions comprising a coding sequence for a toxin polypeptide are provided. The coding sequences can be used in DNA constructs or expression cassettes for transformation and expression in plants and bacteria. Compositions also comprise transformed bacteria, plants, plant cells, tissues, and seeds. In particular, isolated toxin nucleic acid molecules are provided. Additionally, amino acid sequences corresponding to the polynucleotides are encompassed, and antibodies specifically binding to those amino acid sequences. In particular, the present invention provides for isolated nucleic acid molecules comprising nucleotide sequences encoding the amino acid sequence shown in SEQ ID NO:50-96, or the nucleotide sequence set forth in SEQ ID NO:1-47, as well as variants and fragments thereof.Type: GrantFiled: May 13, 2015Date of Patent: May 7, 2019Assignee: BASF Agricultural Solutions Seed US LLCInventors: Kimberly S. Sampson, Daniel John Tomso, Razvan Valeriu Dumitru
-
Patent number: 10280435Abstract: The present invention generally provides improved gene therapy vectors, cell-based compositions, and methods of using the same in methods of gene therapy. The present invention further provides improved gene therapy compositions for expanding hematopoietic cells and related methods for treatment of diseases, disorders, and conditions of the hematopoietic system such as thalassemias and anemias.Type: GrantFiled: October 9, 2017Date of Patent: May 7, 2019Assignee: bluebird bio, Inc.Inventors: Olivier Negre, Emmanuel Payen, Philippe Leboulch, Yves Beuzard
-
Patent number: 10280436Abstract: The present invention relates to stable and high-producing site-specific integration (SSI) host cells, e. g. Chinese hamster ovary (CHO)-derived host cells, methods to produce and to use them.Type: GrantFiled: June 20, 2013Date of Patent: May 7, 2019Assignees: LONZA BIOLOGICS PLC, PFIZER INC.Inventors: James Rance, Robert Young, Michael J. Agostino, Mark Moffat, Lin Zhang, Baohong Zhang
-
Patent number: 10280437Abstract: A method for producing ethanol, which is a method for producing ethanol from a saccharide obtained from biomass, includes a step of adding an additive solution containing at least acetic acid, formic acid, furfural, and hydroxymethylfurfural to the saccharide to prepare a mixed solution containing the saccharide and the additive solution, and a step of adding a microorganism to the mixed solution to ferment the saccharide using the microorganism, thereby producing ethanol.Type: GrantFiled: December 12, 2013Date of Patent: May 7, 2019Assignee: JGC CORPORATIONInventors: Makoto Ikeo, Shohei Okino
-
Patent number: 10280438Abstract: The invention relates to the fields of industrial microbiology and alcohol production including production of yeast products with features suitable for transport, storage, and utilization in fermentation.Type: GrantFiled: August 11, 2015Date of Patent: May 7, 2019Assignee: Butamax Advanced Biofuels LLCInventors: Larry Cameron Anthony, Caroline Peres, Robert Balcarcel
-
Patent number: 10280439Abstract: The present invention relates to a method for a dicarboxylic acid, which method comprises fermenting fungal cells in a vessel comprising a suitable fermentation medium, wherein a least a portion of the fungal cells are reused in the presence of a vitamin and/or a trace element.Type: GrantFiled: July 18, 2014Date of Patent: May 7, 2019Assignees: DSM IP ASSESTS B.V., ROQUETTE FRERES SAInventors: Mickel Leonardus August Jansen, René Verwaal, Laurent Segueilha, Mélanie Louchart, Tania Veiga Dos Inocentes
-
Patent number: 10280440Abstract: [Problems] To provide a method of producing a lipid, containing enhancing productivity of medium chain fatty acids or the lipid containing these medium chain fatty acids as components. [Means to solve] A method of producing a lipid, containing the steps of: culturing a transformant in which a gene encoding any one of the following proteins (A) to (C) is introduced into a host, and collecting a lipid from the cultured product: (A) a protein consisting of the amino acid sequence of the 91st to 348th positions set forth in SEQ ID NO: 1; (B) a protein consisting of an amino acid sequence having 80% or more identity with the amino acid sequence of the 91st to 348th positions set forth in SEQ ID NO: 1, and having acyl-ACP thioesterase activity; and (C) a protein containing the amino acid sequence of the protein (A) or (B), and having acyl-ACP thioesterase activity.Type: GrantFiled: November 6, 2015Date of Patent: May 7, 2019Assignee: Kao CorporationInventor: Tatsuro Ozaki
-
Patent number: 10280441Abstract: The present invention provides for a method of producing a cinnamoyl anthranilate, or analog thereof, in a genetically modified host cell.Type: GrantFiled: October 14, 2011Date of Patent: May 7, 2019Assignee: The Regents of the University of CaliforniaInventors: Dominique Loque, Aymerick Guillaume Eudes
-
Patent number: 10280442Abstract: The present invention relates to glycosylating polyphenols via biocatalysis. More specifically the present invention discloses particular mutants of the thermostable sucrose phosphorylase derived from the microorganism Thermoanaerobacterium thermosaccharolyticum which efficiently glycosylate polyphenols such as resveratrol.Type: GrantFiled: May 10, 2016Date of Patent: May 7, 2019Assignee: UNIVERSITEIT GENTInventors: Tom Desmet, Mareike Dirks-Hofmeister, Karel De Winter, Tom Verhaeghe
-
Patent number: 10280443Abstract: Disclosed is a method for purifying a target protein, comprising steps of: bringing a fusion protein containing an amino acid sequence of a peptide tag, an amino acid sequence of a cleavable site of a protease and an amino acid sequence of a target protein, into contact with the protease in a solution, to cleave the peptide tag from the fusion protein; and bringing the solution containing the peptide tag, the target protein and the protease into contact with an ion exchange resin to separate the target protein and the peptide tag, thereby acquiring a solution containing the target protein, wherein, in the fusion protein, the amino acid sequence of a cleavable site of the protease exists between the amino acid sequence of the peptide tag and the amino acid sequence of the target protein, and the peptide tag is polyanionic or polycationic.Type: GrantFiled: April 6, 2017Date of Patent: May 7, 2019Assignee: SYSMEX CORPORATIONInventor: Ryo Takahashi
-
Patent number: 10280444Abstract: A method of quantitating sorption of stannous by microbial cells of a biofilm is an effective way of assessing efficacy of oral care products containing stannous.Type: GrantFiled: September 9, 2016Date of Patent: May 7, 2019Assignee: THE PROCTER & GAMBLE COMPANYInventors: Yunming Shi, Ross Strand, Jinlan Chang, Tao He, Donald James White, Jr., Yanyan He, Matthew Lloyd Barker, Weili Dong
-
Patent number: 10280445Abstract: The present disclosure relates methods of chromogen layering, wherein a first chromogen and a first stain (color) are produced on a sample, specific for a first analyte, followed by a second chromogen and a second stain (color) being produced on the same sample, specific for a second analyte. In addition, if desired, by overlaying the second stain on top of the first stain, a unique third color is produced that is specific for a third analyte. Therefore, the distribution of different colors throughout the sample could be used to identify at least two or more analytes simultaneously within a single sample.Type: GrantFiled: July 16, 2017Date of Patent: May 7, 2019Assignees: Diagnostic BioSystems, Marc KeyInventors: Bipin Gupta, Marc Key
-
Patent number: 10280446Abstract: The disclosure provides articles and methods useful for detecting a discrete source of DNase activity. DNase-producing microorganisms can be detected. The device can further include selective agents and/or indicators to differentiate groups or species microorganisms. Methods of use include detecting or enumerating DNase-producing microorganisms.Type: GrantFiled: July 17, 2017Date of Patent: May 7, 2019Assignee: 3M Innovative Properties CompanyInventors: Patrick A. Mach, Michelle L. Rosauer, Michael E. Hughes
-
Patent number: 10280447Abstract: Described are substituted imidazo[1,2-a]pyrazine compounds of formula (I), which are coelenterazine analogs, methods for making the compounds, kits comprising the compounds, and methods of using the compounds for the detection of luminescence in luciferase-based assays.Type: GrantFiled: November 1, 2017Date of Patent: May 7, 2019Assignee: Promega CorporationInventors: Mary Hall, Thomas Kirkland, Thomas Machleidt, Anton Shakhmin, Joel R. Walker, Keith V. Wood, Wenhui Zhou
-
Patent number: 10280448Abstract: [Problem] To provide an apparatus for denaturing double strand nucleic acids to single strand nucleic acids, and a method for denaturing double strand nucleic acids to single strand nucleic acids, which may become an alternative means to the thermal denaturation. [Solution] A nucleic acid denaturation apparatus 100 according to the present invention is provided with a vibration generation part 10 for generating vibration to be given to a nucleic acid solution containing double strand nucleic acids, which gives the vibration that occurs in the vibration generation part to the nucleic acid solution, thereby denaturing the double strand nucleic acids in the nucleic acid solution to single strand nucleic acids.Type: GrantFiled: August 28, 2013Date of Patent: May 7, 2019Assignee: KANAGAWA UNIVERSITYInventor: Shigeo Yamaguchi
-
Patent number: 10280449Abstract: Aspects of the present disclosure include methods of producing nucleic acid libraries. In certain aspects, the methods include producing tagged primer extension products, and contacting aliquots of the tagged primer extension products with transposomes to produce tagged extension product fragments. The methods may further include sequencing the tagged extension products and tagged extension product fragments to determine the sequences of nucleic acids of interest. Also provided are compositions and kits that find use, e.g., in practicing embodiments of the methods.Type: GrantFiled: June 28, 2016Date of Patent: May 7, 2019Assignee: The Regents of the University of CaliforniaInventors: Christopher Vollmers, Charles Cole
-
Patent number: 10280450Abstract: Provided are methods and devices for detection of unlabeled nucleic acids. The detection methods are based on change of solubility of hydrophobic probes upon hybridization with a polynucleotide. In one embodiment, the probes are morpholino probes, having a fluorophore attached thereto. The morpholino probes are immobilized on a substrate that has fluorescence quenching functionality.Type: GrantFiled: November 13, 2014Date of Patent: May 7, 2019Assignee: New York UniversityInventors: Rastislav Levicky, Wanqiong Qiao, Yatao Liu
-
Patent number: 10280451Abstract: Methods, compositions, and kits are provided for quantification of genome editing.Type: GrantFiled: January 8, 2016Date of Patent: May 7, 2019Assignees: Bio-Rad Laboratories, Inc., J. David Gladstone InstitutesInventors: Jennifer Berman, Samantha Cooper, George Karlin-Neumann, Yuichiro Miyaoka, Bruce Conklin, Josh Shinoff
-
Patent number: 10280452Abstract: A method and an oligonucleotide probe are described for determining the presence or absence of mutant alleles in a genomic locus. The probe binds to different alleles of a target sequence with different melting temperatures (Tm). The method determines the Tm of the probe when it is hybridized to the target sequence to establish whether a variant nucleic acid such as a mutant allele is present or absent in the target sequence. There may be variants in a target sequence that are not of interest, for example phenotypically silent mutations. To ensure that these variants do not influence the Tm of the probe, the probe contains universal base sites where such variants of no interest occur.Type: GrantFiled: September 30, 2014Date of Patent: May 7, 2019Assignee: Genedrive Diagnostics, Ltd.Inventor: Ben Cobb
-
Patent number: 10280453Abstract: The present invention relates to the detection of a target nucleic acid sequence by a PTOCE (PTO Cleavage and Extension) assay. The present invention detects a target nucleic acid sequence in which the PTO (Probing and Tagging Oligonucleotide) hybridized with the target nucleic acid sequence is cleaved to release a fragment and the fragment is hybridized with the CTO (Capturing and Templating Oligonucleotide) to form an extended duplex, followed by detecting the presence of the extended duplex. The extended duplex provides signals (generation, increase, extinguishment or decrease of signals) from labels indicating the presence of the extended duplex and has adjustable Tm value, which are well adoptable for detection of the presence of the target nucleic acid sequence.Type: GrantFiled: June 16, 2016Date of Patent: May 7, 2019Assignee: SEEGENE, INC.Inventors: Jong Yoon Chun, Young Jo Lee